Role of Mepolizumab in COVID Patients with Severe Eosinophilic Asthma

Authors

  • Azmat Karim Department of Respiratory Medicine, Jawahar Lal Nehru Medical College and Hospital, Aligarh Muslim University, Aligarh, Uttar Pradesh, India. Author
  • Mohammad Shameem Department of TB and Respiratory Diseases, Jawahar Lal Nehru Medical College and Hospital Aligarh Muslim University, Aligarh, Uttar Pradesh, India Author
  • Anjana Talwar Department of Physiology, All India Institute of Medical Science, New Delhi, India Author
  • Deepak Talwar Director and Head Metro Centre for Respiratory Diseases, Metro Hospital Noida, Uttar Pradesh, India Author
  • Abdul Allam Khan Resident Cardiology, Fortis Escorts Heart Institute, Okhla, New Delhi, India Author

DOI:

https://doi.org/10.47363/JPRR/2024(6)171

Keywords:

COVID-19, Mepolizumab, Severe Eosinophilic Asthma, Comorbidity

Abstract

Aim: To evaluate the effect of Mepolizumab on COVID-19 patients with severe eosinophilic asthma and other comorbidities.

Methods: 11 patients on Mepolizumab to treat SEA and contracted COVID-19 were taken. The retrospective clinical, demographical, and biochemical data were collected and evaluated.

Results: Out of the 11 patients infected with COVID-19, 6 were males and 5 were females, with a mean age of 58. The most common risk factor was Hypertension (54%), Diabetes (36%), Obstructive sleep apnea (36%), and coronary artery disease (27%). Four out of 11 are above the age of 60, and half of the patients were overweight. Despite having multiple comorbidities, none of the patients required admission to the hospital.

Conclusions: Patients who were administered mepolizumab and were diagnosed with COVID-19 only experienced mild symptoms and did not suffer from any complications despite having multiple comorbidities. This suggests that there may be a positive effect of mepolizumab on the course of COVID-19 or that it could be associated with asthma. However, further, larger-scale studies are required to determine the role of mepolizumab in COVID-19 and to explore its potential as a protective effect against the disease.

Author Biographies

  • Azmat Karim, Department of Respiratory Medicine, Jawahar Lal Nehru Medical College and Hospital, Aligarh Muslim University, Aligarh, Uttar Pradesh, India.

    Azmat Karim, Department of Respiratory Medicine, Jawahar Lal Nehru Medical College and Hospital, Aligarh Muslim University, Aligarh, Uttar Pradesh, India.

  • Mohammad Shameem, Department of TB and Respiratory Diseases, Jawahar Lal Nehru Medical College and Hospital Aligarh Muslim University, Aligarh, Uttar Pradesh, India


    Department of TB and Respiratory Diseases, Jawahar Lal Nehru Medical College and Hospital Aligarh Muslim University, Aligarh, Uttar Pradesh, India

  • Anjana Talwar, Department of Physiology, All India Institute of Medical Science, New Delhi, India

    Department of Physiology, All India Institute of Medical Science, New Delhi, India

  • Deepak Talwar, Director and Head Metro Centre for Respiratory Diseases, Metro Hospital Noida, Uttar Pradesh, India

    Director and Head Metro Centre for Respiratory Diseases, Metro Hospital Noida, Uttar Pradesh, India

  • Abdul Allam Khan, Resident Cardiology, Fortis Escorts Heart Institute, Okhla, New Delhi, India

    Resident Cardiology, Fortis Escorts Heart Institute, Okhla, New Delhi, India

Downloads

Published

2024-03-26

Issue

Vol. 6 No. 3 (2024): Volume 6 Issue 3

Section

Articles